The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models

Fabry disease is an X-linked multisystemic disorder caused by the impairment of lysosomal α-Galactosidase A, which leads to the progressive accumulation of glycosphingolipids and to defective lysosomal metabolism. Currently, Fabry disease is treated by enzyme replacement therapy or the orally admini...

Descripció completa

Dades bibliogràfiques

Autors principals:	Pedro Besada, María Gallardo-Gómez, Tania Pérez-Márquez, Lucía Patiño-Álvarez, Sergio Pantano, Carlos Silva-López, Carmen Terán, Ana Arévalo-Gómez, Aurora Ruz-Zafra, Julián Fernández-Martín, Saida Ortolano
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2021-12-01
Col·lecció:	Biomolecules
Matèries:	Fabry disease pharmacological chaperones <i>GLA</i> variants Migalastat lysosomal storage diseases
Accés en línia:	https://www.mdpi.com/2218-273X/11/12/1856
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!